Philippe Courtet, MD, PhD,a,b,* and Bénédicte Nobile, Pharm D, PhD a,b
Published online: May 12, 2020.
a PSNREC, Université Montpellier, INSERM, CHU de Montpellier, Montpellier, France
b Department of Psychiatric Emergency & Acute Care, Lapeyronie Hospital, CHU Montpellier, Montpellier, France
*Corresponding author: Philippe Courtet, MD, PhD, Université Montpellier, CHRU Montpellier, Montpellier, France 34090 (philippe.courtet@univ-montp1.fr).
J Clin Psychiatry 2020;81(3):20com13276
J Clin Psychiatry. 2020;81(3):20com13276.
To share: https://doi.org/10.4088/JCP.20com13276
It is important to thank Dr Iltis and collaborators for tackling, in their recent article,1 a crucial issue: the almost systematic exclusion of suicidal patients from clinical trials on antidepressants. The exclusion of these individuals is particularly critical given that suicidal behavior is a leading cause of death (about 800,000 deaths by suicide per year worldwide) with very few specific treatments.2...
Lire la suite https://www.psychiatrist.com/JCP/article/Pages/2020/v81/20com13276.aspx